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ABSTRACT
We previously found that the splicing of exon 5 to exon
6 in the rat /3-TM gene required that exon 6 first be
joined to the downstream common exon 8 (Helfman et
al., Genes and Dev. 2,1627-1638,1988). Pre-mRNAs
containing exon 5, intron 5 and exon 6 are not normally
spliced in vitro. We have carried out a mutational
analysis to determine which sequences in the pre-
mRNA contribute to the inability of this precursor to
be spliced in vitro. We found that mutations in two
regions of the pre-mRNA led to activation of the
3'-splice site of exon 6, without first joining exon 6 to
exon 8. First, introduction of a nine nucleotide poly U
tract upstream of the 3'-splice site of exon 6 results in
the splicing of exon 5 to exon 6 with as little as 35
nucleotides of exon 6. Second, introduction of a
consensus 5'-splice site in exon 6 led to splicing of
exon 5 to exon 6. Thus, three distinct elements can act
independently to activate the use of the 3'-splice site
of exon 6: (1) the sequences contained within exon 8
when joined to exon 6, (2) a poly U tract in intron 5,
and (3) a consensus 5'-splice site in exon 6. Using
biochemical assays, we have determined that these
sequence elements interact with distinct cellular factors
for 3'-splice site utilization. Although HeLa cell nuclear
extracts were able to splice all three types of pre-
mRNAs mentioned above, a cytoplasmic S100 fraction
supplemented with SR proteins was unable to
efficiently splice exon 5 to exon 6 using precursors in
which exon 6 was joined to exon 8. We also studied
how these elements contribute to alternative splice site
selection using precursors containing the mutually
exclusive, alternatively spliced cassette comprised of
exons 5 through 8. Introduction of the poly U tract
upstream of exon 6, and changing the 5-splice site of
exon 6 to a consensus sequence, either alone or in
combination, facilitated the use of exon 6 in vitro, such
that exon 6 was spliced more efficiently to exon 8.
These data show that intron sequences upstream of an
exon can contribute to the use of the downstream
5'-splice, and that sequences surrounding exon 6 can
contribute to tissue-specific alternative splice site
selection.
INTRODUCTION
A major unresolved question in pre-mRNA splicing is how exons
are spliced together with such fidelity in genes that contain
multiple exons. In addition, how alternatively spliced exons are
chosen is largely unknown. Alternative RNA splicing is a
fundamental process in eukaryotes, that contributes to tissue-
specific and developmentally regulated patterns of gene
expression (1,2). At present relatively little is known about the
cellular factors and mechanisms that are responsible for the
selection of alternative splice sites in complex transcription units
and how the splicing signals in alternatively spliced exons differ
from those in constitutively spliced exons (for reviews see 1 -4 ) .
Significant progress has been made in Drosophila systems such
as in the genes of the sex determination pathway, suppressor of
white apricot and Drosophila P-transposase. In these systems
alternative splicing is subject to regulation by factors that either
inhibit or activate the use of alternative 5' or 3' splice sites
(1,3-5). In contrast, in vertebrate systems, much less is known
about the mechanisms and cellular factors involved in the
regulation of alternative splicing, but a number of features in the
pre-mRNA have been implicated in alternative splice site
selection. These include the relative strengths of 5' and 3' splice
sites (6-9), intron size (10), the pyrimidine content of a 3' splice
site (7,11,12), the location of branch points (13-18), multiple
alternative branch points (14,16,19,20), branch point sequences
(7,21-24), intron sequences between a 3' splice site and
upstream branch point (15,17,25), and exon sequences
(11,13,25-39).
In addition to cis-acting elements in the pre-mRNA, at least
one cellular factor isolated from mammalian cells termed ASF
(alternative splicing factor) or SF2, has been found to affect the
choice of alternative 5' splice sites (40,41). In vitro splicing
studies with pre-mRNA derived from the early region of simian
virus (SV40) involving the alternative splicing of large T and
small t splice sites, and with model pre-mRNA substrates derived
from the human /3-globin gene demonstrated that high
concentrations of SF2/ASF promote the use of proximal 5' splice
sites, whereas low concentrations favor the use of distal 5' splices
(40,41). Although this factor is also required for general splicing
(42), differences in the relative concentrations or activities of this
factor in different cell types might play a role in regulated
alternative splicing. In addition, hnRNP Al can antagonize the
effects of SF2/ASF (43), but this effect appears to be specific
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Figure 1. Organization of the rat (3-tropomyosin gene. Open boxes represent constitutive exons, hatched and closed boxes represent tissue-specific exons as indicated.
Horizontal lines represent introns; they are not drawn to scale. The amino acids encoded by each exon are indicated. The CAP site and polyadenylation sites are also indicated.
to only certain introns (44). SF2/ASF is part of a family of
proteins termed SR proteins (45). Interestingly, different SR
proteins have distinct functions in alternative pre-mRNA splicing
in vitro and different members of the SR protein family are
differentially expressed in various tissues and cell types (46).
Collectively, these studies show that modulation of alternative
splice site selection can, in principle, be achieved by changes
in the levels of general splicing factors.
We have been using the rat jS-tropomyosin (TM) gene as a
model system to investigate the mechanisms responsible for
developmental and tissue-specific alternative RNA splicing
(16,17,25,30,32,47). This gene spans 10 kb of DNA with 11
exons and encodes two distinct isoforms, namely skeletal muscle
/3-TM and fibroblast TM-1 (Figure 1). Exons 1 through 5, 8 and
9 are common to all mRNAs expressed from this gene. Exons
6 and 11 are used in fibroblasts as well as smooth muscle,
whereas exons 7 and 10 are used exclusively in skeletal muscle.
We have found that use of the skeletal muscle exon 7 in
nonmuscle cells is blocked in nonmuscle cells due to the
interaction of factors with sequences upstream and within exon
7 (17,25,47). Our previous studies involving the use of exon 6
(nonmuscle-type splice) revealed an ordered pathway of splicing
in which exon 6 must first be joined to the downstream common
exon before it can be spliced to the upstream common exon (32).
Pre-mRNAs containing exon 5, intron 5 and exon 6 are not
normally spliced in vitro.
We have carried out a mutational analysis to determine which
sequences in the pre-mRNA contribute to the inability of this
precursor to be spliced in vitro. Our studies demonstrate that three
distinct elements can act independently to activate the use of the
3'-splice site of exon 6. Using biochemical assays, we have
determined that these sequence elements interact with distinct
cellular factors for 3'-splice site utilization. We also find that
introduction of a poly U tract in the intron upstream of exon 6
can contribute to die use of the downstream 5'-splice site. These
results also demonstrate that, in addition to sequences in and
around exon 7 (skeletal muscle-type splice), multiple cis-elements
surrounding exon 6 contribute to tissue-specific alternative splice
site selection.
MATERIALS AND METHODS
Plasmid constructions
The DNA templates for use in in vitro transcription with SP6
polymerase are derived from the rat /3-TM gene (16,32).
Mutations were introduced by the method of Kunkel (48), and
the DNA sequences confirmed by the method of Sanger (49).
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Figure 2. Nucleotide sequence of two mutations made in the 5' and 3' splice
sites of exon 6. The wild-type (wt) nucleotide sequence at the 3' end of intron
5 and the 5'-splice site of exon 6 are shown. Also shown here is the UlsnRNA
sequence complementary to the 5'-splice site of exon 6.
Synthesis of RNA and in vitro splicing
The 32P-labelled SP6/tropomyosin pre-mRNAs were synthesized
in vitro primed with CAP analog as described (50). The pre-
mRNAs contained a small amount of prematurely terminated
transcripts, but their presence did not appear to affect the in vitro
splicing reactions and the RNA substrates were not further
purified.
HeLa cell nuclear extracts we prepared as described (51,52).
In vitro splicing reactions were carried out at 30° for indicated
times (0-240 min). Standard assay conditions used for these
studies consisted of 15 i^l of nuclear extract in a final reaction
volume of 25 pi containing 2 MgCl2, 500 /*M ATP, 20 mM
creatine phosphate, 2.6% (w/v) polyvinyl alcohol, 15-30 ng pre-
mRNA, 12.8 mM HEPES (pH 8), 12% (v/v) glycerol, 60 mM
KC1, 0.12 mM EDTA and 0.3 mM DTT. In some experiments
the concentrations of MgCl2 and KC1 were varied as indicated.
The complementation assay was carried out in the presence
of a HeLa cell cytoplasmic SI00 fraction with or without the
addition of SR proteins in in a 25 nl volume, containing 6 /i\
of HeLa cell SI00 and 4 /*1 of buffer D or buffer D containing
different dilutions of SR proteins. The SR proteins were prepared
as described (46).
Analysis of processing products
After incubation for indicated time the reactions were stopped
by addition of a solution containing SDS-proteinase K and the
RNA was recovered as described (52). The products of the
reaction were analyzed on 4% acrylamide/7M urea gels.
Intermediates were distinguished from final products by their
relative appearance and disappearance in time course
experiments. Lariat RNAs were identified by their aberrant
mobility on different percentage polyacrylamide gels (53). In
addition, RNAs containing lariats were verified by treatment by
a lariat debranching activity (54).
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Figure 3. /n vitro splicing of pre-mRNAs containing mutations in the 5' and
3' splice sites of exon 6. In vitro splicing reactions were carried out for 2 hours
and the 32P-RNA products were separated in a 4% denaturing polyacrylamide
gel. The assay conditions used for these studies consisted of 15 /A of nuclear
extract in a final reaction volume of 25 yX containing 1 mM or 3 mM MgCl2,
500 nM ATP, 20 mM creatine phosphate, 2.6% (w/v) polyvinyl alcohol, 15-30
ng pre-mRNA, 12.8 mM HEPES (pH 8), 12% (v/v) glycerol, 60 mM KC1, 0.12
mM EDTA and 0.3 mM DTT. Schematic representation of the products and
intermediates are indicated on the left and right of the panel; from top to bottom
are: i) pre-mRNA, ii) lariat/exon intermediate, iii) free lariat, iv) free lariat but
3' end is degraded up to the lariat branch points by 3' exonucleolytic activity,
v) splice product, vi) free exon 5. Lanes marked M are markers using pBR322
digested with Mspl. Schematic diagrams of the pre-mRNAs used are shown on
the right.
RESULTS
Different elements can activate the 3' splice site of exon 6
The splicing of exon 5 to exon 6 requires that exon 6 first be
spliced to the downstream common exon 8 (32). Pre-mRNAs
containing exon 5, intron 5 and exon 6 are not normally spliced
in vitro. Therefore, the nucleotide sequences within exon 6 and
the adjacent upstream intron does not seem to contain sufficient
information to be recognized as a 3'-splice site by the splicing
machinery. We have carried out a mutational analysis to
determine which sequences in the pre-mRNA contribute to the
inability of this precursor to be spliced in vitro. Two types of
mutations were made in the 5' and 3' splice sites of exon 6 (Figure
2). The first one introduced a nine nucleotide stretch of poly U
in the 3'-splice site of exon 6. The second mutation changed the
5'-splice site of exon 6 to a Ul consensus binding site. 32P-
labeled pre-mRNAs containing these mutations were synthesized
and tested in vitro (Figure 3). In agreement with our previous
studies, precursors containing only the 5'-half of exon 6
(generated from the template linearized at an Ncol site in the
middle of exon 6) or those containing all of exon 6 and 17
nucleotides of downstream intron were not spliced under assay
conditions using 1 mM or 3 mM MgCl2 (Figure 3, lanes 1 and
2). In contrast, precursors containing a nine nucleotide poly U
tract in the 3'-end of intron 5 were efficiently spliced (Figure
3, lanes 4 and 5) even with as little as 35 nucleotides of exon
6 (Figure 3, lane 4). Introduction of a consensus 5'-splice site
Figure 4. Analysis of in vitro splicing products of tropomyosin pre-mRNAs. Time
course (in minutes) of formation of spliced products from different pre-mRNAs
derived from the (3-TM gene. The assay conditions were the same as described
in Figure 3, except 1 mM MgCI2 was used here. Schematic representation of
products are indicated; the boxes represent exon sequences and the lines intron
sequences.
in exon 6 led to splicing of exon 5 to exon 6 (Figure 3, lane
3). The results obtained with the consensus 5'-splice site in exon
6 are in agreement with the exon definition model (55). However,
pre-mRNAs containing this mutation were spliced less efficiently
(Figure 3, lane 3), compared to the mutants containing the poly
U tract (Figure 3, lanes 4 and 5) or when exon 8 was joined
to 6 (Figure 3, lanes 7 and 8). We also performed a time course
study using the different pre-mRNAs described in Figure 3. The
splicing reactions were carried out for 0, 15, 30, 60, 90 and 120
min, respectively (Figure 4). The wild-type pre-mRNA was not
spliced at all . Interestingly. pre-mRNAs containing the poly U
tract exhibited somewhat more rapid kinetics, as indicated by
the appearance of splicing intermediates, i.e., free exon 5 and
the lariat/exon intermediate, at as early as 30 min incubation.
On the other hand, constructs containing exon 6 joined to exon
8 (p4d52 and p4d20) exhibited a somewhat slower rate of splicing
kinetics. Again, pre-mRNAs containing the consensus sequence
in the 5'-splice site of exon 6 was spliced less efficiently, and
splice products were not detected until after 90 min. incubation.
Thus these sequence elements exhibited different relative strengths
with respect to their ability to activate the 3'-splice site of exon
6 presumably by interacting with distinct cellular factors (see
below). Furthermore, these studies demonstrate that three distinct
sequence elements can act independently to activate the use of
the 3'-splice site of exon 6: (1) the sequences contained within
exon 8 when joined to exon 6 (exon-recognition element), (2)
a poly U tract in intron 5, and (3) the 5'-splice site of exon 6.
Effects of mutations in the 5' and 3' splice sites of exon 6
on alternative splice site selection
It was of interest to determine how these mutations in the 5'-
and 3'-splice sites of exon 6 would affect alternative splice site
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Figure 5. Effect of poly U and exon 6 consensus 5'-splice site on alternative splicing of /3-tropomyosin pre-mRNA. (Panel A) Effect of magnesium concentration
on alternative splicing in vitro. Tropomyosin pre-mRNAs derived from pSP64-p2p6 linearized with Cla] were processed for 2 h in vitro using the assay conditions
described in Figure 3 except the magnesium concentration was varied as indicated at the top of the figure. The splicing products were analyzed on a 4% polyacrylamide
denaturing gel. Schematic representation of the products are shown. The markers are 32P-labelled Msp I fragments of pBR322 (M).(Panel B) Time course (in minutes)
of formation of spliced products from transcripts terminating at the Clal site of plasmids pSP64-p2p6. The 32P-RNA products were separated in 4% denaturing
polyacrylamide gels. The assay conditions used for were the same as described in Figure 3, except that 3 mM MgCl2 was used here. Schematic representation of
products and intermediates are shown.
selection using precursors containing the mutually exclusive,
alternatively spliced cassette comprised of exons 5 — 8 (Figure
5). We analyzed the splicing of pre-mRNAs derived from
pSP64-p2p6 linearized with Clal (32). We previously found that
alteration in magnesium concentration affect the choice of splice
sites using the wild-type p2p6 pre-mRNA (32). Therefore, we
examined the effects of changing the concentrations of MgCl2
on splice site utilization in pre-mRNAs containing the mutations
mentioned above. In agreement with our previous studies, at 1
mM MgCl2 the wild-type pre-mRNA exhibited exon-skipping,
i.e., joining exon 5 to exon 8 (Fig. 5). As the MgCl2
concentration was increased above 1 mM, cleavage at the 5' splice
site of exon 6 as well as splicing of exon 6 to exon 8 were
detected. Splicing for all pre-RNAs was found to be inhibited
at 5 mM MgCl2. In contrast, splicing of the precursor
containing the consensus in the 5'-splice site of exon 6 was no
longer sensitive to changes in the MgCl2. Although this
precursor still produced some exon skipping product, there was
substantial amount of the product formed from splicing exon 6
to 8. In addition, there was only very low levels of fully-spliced
RNA i.e., exons 5 + 6 + 8+9. In vitro splicing of the pre-mRNA
containing the poly U tract at the 3'-end of intron 5 not only
facilitated the splicing of exon 6 to 8, but also resulted in
substantial amounts of fully-spliced pre-mRNA, i.e., exons
5+6 + 8 + 9. Finally, combining the poly U tract and consensus
site in exon 6 had an additive effect. This double mutant precursor
no longer exhibited any exon skipping, and produced significantly
higher levels of fully spliced pre-mRNA.
Our previous studies demonstrated that there was an ordered
pathway involved in utilization of exon 6, in which splicing of
exon 6 to exon 8 preceded splicing of exon 5 to exon 6. We
wished to determine if the poly U tract and consensus 5'-splice
site would alter this ordered pathway. Therefore, we examined
splicing pathways of the different tropomyosin pre-mRNAs in
greater detail by carrying out a time course study (Figure 5, right
panel). Both the wild-type precursor and the mutant precursor
with the consensus 5' splice site in exon 6 produced only two
splice products, exons 5+8+9 (exon skipping) and exon 6 joined
to exon 8. Neither substrate exhibited splicing of exon 5 to 6.
Thus, the major effect of introducing a consensus 5'-splice site
in exon 6 is promoting the splicing of exons 6 to 8. The time
course of in vitro splicing of pre-mRNAs containing poly U tract
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Figure 6. Effect of competitor RNAs on splicing z'n vitro. Tropomyosin pre-
mRNAs derived from p4d52 and poly U tract-containing plasmids that were
linearized with Clal were processed for 2 h using the assay conditions described
in Figure 3 except 10 JL\ of nuclear extract (NE) were used in a final reaction
volume of 25 /tl, in the presence of increasing concentrations of competitor RNAs.
The splicing products were analyzed on a 4% polyacrylamide/UREA gel.
Schematic representation of the precursors, intermediates, and products are
indicated.
in intron 5, either alone or in combination with the consensus
5'-splice site in exon 6, revealed a preferred order of intron
removal where exon 6 was first spliced to exon 8 before being
spliced to the upstream exon 5. These data demonstrate that
introduction of the poly U tract upstream of exon 6 and changing
the 5'-splice site of exon 6 to a consensus sequence, either alone
or in combination, facilitates the use of exon 6 in vitro, such that
exon 6 is spliced more efficiently to exon 8, indicating that intron
sequences upstream of an exon can contribute to the use of the
downstream 5'-splice site. These results also demonstrate that,
in addition to sequences in and around exon 7 (17, 25), multiple
cis-elements surrounding exon 6 may also contribute to tissue-
specific alternative splice site selection of /3-TM pre-mRNA.
Distinct factors are required for different 3-splice sites
The results presented above indicate that three distinct sequence
elements can act independently to activate the 3'-splice site of
exon 6. In order to determine if the activation by the poly U
tract and by the sequence in exon 8 involved the same factors,
we carried out an in vitro competition experiment using two kinds
of competitor RNAs. One competitor had the sequence of the
3'-half of exon 6 joined to the 5'-half of exon 8, and the other
contained exon 7 and the flanking intron sequences (Figure 6).
In vitro splicing of the precursor containing exon 6 joined to exon
8 (p4d52 substrate) or containing the poly U tract in intron 5
was carried out in the absence or presence of increasing
concentrations of competitor RNAs (Figure 6). Addition of the
competitor RNA which contained sequences in and around exon
7 had virtually no effect on the splicing efficiency of either pre-
mRNA. However, addition of the competitor which contained
sequences in exons 6 and 8 inhibited the splicing of the p4d52
precursor. On the other hand, this competitor had no effect on
the splicing of the pre-mRNA containing the poly U tract in the
3'-end of intron 5.
The data from the above experiments strongly suggest that
distinct factors are required for the use of the 3'-splice site in
exon 6 in the poly U tract containing and p4d52 substrates. In
order to identify these factors we have begun to develop in vitro
systems to assay for these 3'-splice site splicing factors. We first
tested the ability of four different pre-mRNAs to be spliced in
a restrictive splicing system comprised of a HeLa cell S100
fraction and SR proteins (Fig. 7). The pre-mRNAs used were
p7(8/9), p5 poly U, p5 Ex6 consensus, and p4d52. Although all
four precursors were able to be spliced in HeLa cell nuclear
extracts, only two were spliced efficiently in the complementation
assay using the HeLa cell S100 fraction plus SR proteins. Both
p7(8/9) and p5 poly U pre-mRNAs were spliced in the presence
of S100 plus SR proteins. By contrast, the p5 Ex6 consensus
and the p4d52 pre-mRNAs were spliced relatively inefficiently.
The difference between the ability of the p5 poly U and p4d52
pre-mRNAs to be spliced in the presence of S100 and SR proteins
again suggests that use of the 3'-splice site in exon 6 in these
two precursors require distinct factors. Thus it appears that the
SI 00 fraction contains a limiting amount of a factor(s), other than
SR proteins, that is required for splicing the p4d52 pre-mRNA.
Work is currently in progress to identify this activity.
DISCUSSION
Cis-elements involved in alternative splice site selection in /3-
TM pre-mRNA
Our previous studies demonstrated that the nucleotide sequences
contained in exon 6 itself do not contain sufficient information
to interact with splicing factors to form a functional splicing
complex with respect to utilization of its 3'-splice site (32). The
present work extended these studies and showed that three distinct
elements could act independently to activate the 3'-splice site of
exon 6: (1) the sequences contained within exon 8 when joined
to exon 6 (exon recognition element), (2) a poly U tract
introduced in 3'-end of intron 5, and (3) a consensus 5'-splice
site introduced in exon 6. We also investigated the effects these
elements exerted on alternative splice site selection. We found
that the poly U tract in intron 5 or the consensus 5'-splice site
in exon 6, either alone or in combination, facilitated the splicing
of exon 6 to exon 8. Thus, sequences in the 3'-splice site of exon
6 were found to facilitate the use of the downstream 5'-splice
site of this exon (Figure 5). The mechanism by which the
activation by these elements occurs is presently unknown. What
factors the poly U tract recruits remains to be determined. It is
possible that the poly tract simply serves as a better binding site
for factors such as U2AF (56), and thereby promotes the binding
of U2 snRNP which in turn facilitates the binding of Ul to the
downstream 5'-splice site. In the exon definition model recently
proposed by Berget and colleagues, exons are recognized and
defined as units during early spliceosome assembly by factors
that recognize the 3' and 5' splice sites bordering an exon (55).
A number of laboratories have found that sequences at the
5'-splice site of an exon facilitates the use of the upstream
3'-splice site (6,8,55,57). The experiments presented here are
in agreement with the exon definition, that is, sequences upstream
of an exon can facilitate use of the downstream 5'-splice site.
It is worth noting that both mutations in the 3' or 5' splice site
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Figure 7. Effects of SR proteins on splicing of different /3-tropomyosin pre-mRNAs in vitro. The names and structures of the RNAs are shown on the top and
side of the panels. Each pre-mRNA was spliced in the presence of nuclear extract (NE) or SlOO plus increasing amounts of SR proteins. The positions of the pre-
mRNAs. products and intermediates are indicated.
of exon 6 facilitated the joining of exon 6 to exon 8 before the
splicing of exon 5 to 6. Thus there was still a preferred order
of intron removal. Interestingly, introduction of a 5'-splice site
consensus in exon 6 promoted the joining of exon 5 to 6 in the
absence of exon 8, but this effect was rather weak (Figure 3,
lanes 3). However, the presence of both a consensus 5'-splice
site in exon 6 and a polu U tract in intron 5 promoted the
formation of fully spliced product. Collectively, these results
suggest that distinct factors are likely interacting with these
elements.
Previous studies from our laboratory have shown that use of
the skeletal muscle exon 7 in nonmuscle cells is blocked by factors
that interact with sequences within exon 7 and the adjacent
upstream intron (17,25,30,47). The results reported here
demonstrate that, in addition to sequences in and around exon
7, multiple cis-acting elements surrounding exon 6 (nonmuscle-
type splice) also contribute to tissue-specific alternative splice
site selection.
Distinct factors are likely required for certain 3'-splice sites
A number of sequence elements are known to play a role in the
use of a 3'-splice site, including the branch point sequence and
its adjacent polypyrimidine tract, as well as sequences contained
within the adjacent downstream exon (reviewed in 58). The
results in the present studies provide biochemical evidence that
different factors are required for the use of certain 3'-splice sites.
Using biochemical assays, we have determined that at least two
of these sequence elements interact with distinct factors for
3'-splice site utilization. First, using a competition assay we were
able to show the presence of a putative trans-acting factor specific
for the p4d52 pre-mRNA. Although addition of a competitor
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Figure 8. Position of purine-rich motifs in /3-TM pre-mRNA. (top) The position
of the purine-rich motifs are indicated by shaded regions in exons 6 and 8. Exon
6 contains two motifs and exon 8 contain three motifs, (lower) sequences of the
five identified motifs and the sequence of a putative consensus motif as proposed
by Xu el at., 1993 (55).
RNA containing sequences from exon 6 and 8 inhibited the
splicing of exon 5 to exon 6 with the p4d52 pre-mRNA, it had
virtually no effect on the poly U tract-containing substrate (Figure
6). Second, HeLa cell nuclear extracts were able to splice three
different pre-mRNAs used in the present studies, that contained
the three sequence elements, respectively, but an SlOO faction
plus SR proteins was only able to support the splicing of exon
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5 to exon 6 in the poly U tract containing pre-mRNA (Figure
7). In the latter assay conditions, pre-mRNA containing exon
6 joined to exon 8 or containing a consensus 5'-splice site in exon
6 was spliced poorly.
A purine-rich element within exon 8 likely serves as a splicing
signal
Our data indicates that sequences in exon 8 contain an important
determinant in 3'-splice site selection. The joining of exon 8 to
exon 6 juxtaposes a splicing signal that thereby activates the
3'-splice site of exon 6. A purine-rich motif that appears to act
as a general splicing signal for 3'-splice sites has been identified
in the mouse immunoglobulin \i (IgM) and chicken cardiac
troponin-T genes (38,39). A similar motif has been found at the
5'-end of exon 8 of the rat /3-TM gene (Figure 8). Two additional
purine-rich motifs are located in exon 8. However, our present
and previous studies demonstrate that pre-mRNAs containing only
26 nucleotides of exon 8 are required for the splicing of exon
5 to exon 6, while pre-mRNAs containing less than 12 nucleotides
of exon 8 are not processed (32, and present studies). Thus it
appears that sequences within the first purine-rich motif in exon
8 are sufficient for activating the exon 5 to exon 6 splice.
Additionally, exon 6 contains two copies of the purine-rich motif.
Although these sequences alone are not sufficient for promoting
the use of the 3'-splice site of exon 6 (Figure 3), it remains to
be determined if these elements are required together with
sequences contained within exon 8. In this regard, work on the
mouse IgM gene demonstrated that multiple elements were
required (38).
Studies of the rat preprotachykinin gene have also shown that
alternative RNA splicing proceeds through an ordered pathway
(8). In this example, the splicing of the alternative exon to the
upstream exon cannot occur until the downstream common exon
is first joined to the alternative exon. Interestingly, the critical
cis-acting element for the use of the alternative exon in
preprotachykinin pre-mRNA is located at the 5' splice site of
the downstream common exon. Joining of the downstream
common exon to the alternative exon promotes the binding of
the U2snRNP to the upstream 3'-splice site of alternative exon
in agreement with exon-definition model (55,57). This is
somewhat different than in the case of /3-TM, where a purine-
rich motif in exon 8 provides the critical cis-element for activation
of the 3' splice site of exon 6. Our results suggest that splicing
factors cannot bind or recognize the purine-rich motif in exon
6, but requires the purine-rich motif in exon 8. Work on the IgM
\i gene indicates that multiple elements are required for activation.
Whether the sequence elements in both exons 6 and 8 are required
for 3'-splice site activation remains to be determined.
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